This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (63)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Controlled, Multicenter Study

Frederick R. Singer, MD; Paul S. Ritch, MD; Thomas E. Lad, MD; Q. Scott Ringenberg, MD; Joan H. Schiller, MD; Robert R. Recker, MD; Elisabeth Ryzen, MD

Arch Intern Med. 1991;151(3):471-476.

Abstract
In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.

(Arch Intern Med. 1991;151:471-476)

Author Affiliations
the Hypercalcemia Study Group

From the Los Angeles County-University of Southern California Medical Center, Los Angeles (Drs Singer and Ryzen); Medical College of Wisconsin, Milwaukee (Dr Ritch); University of Illinois College of Medicine, Chicago (Dr Lad); Veterans Administration Hospital, Columbia, Mo (Dr Ringenberg); University of Wisconsin, Center for Health Sciences, Madison (Dr Schiller); and Creighton University School of Medicine/St Joseph Hospital, Omaha, Neb (Dr Recker).

Footnotes
Accepted for publication August 13, 1990.

Reprint requests to Cedars-Sinai Bone Center, Suite 1004,444 S San Vicente Blvd, Los Angeles, CA 90048 (Dr Singer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Narrative Review: Furosemide for Hypercalcemia: An Unproven yet Common Practice
LeGrand et al.
ANN INTERN MED 2008;149:259-263.
ABSTRACT | FULL TEXT  

Common acute oncological emergencies: diagnosis, investigation and management
Walji et al.
Postgrad. Med. J. 2008;84:418-427.
ABSTRACT | FULL TEXT  

Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone
Clines and Guise
Endocr Relat Cancer 2005;12:549-583.
ABSTRACT | FULL TEXT  

Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Licata
The Annals of Pharmacotherapy 2005;39:668-677.
ABSTRACT | FULL TEXT  

Systematic review of bisphosphonates for hypercalcaemia of malignancy
Saunders et al.
Palliat Med 2004;18:418-431.
ABSTRACT  

Tuberoinfundibular Peptide (7-39) [TIP(7-39)], a Novel, Selective, High-Affinity Antagonist for the Parathyroid Hormone-1 Receptor with No Detectable Agonist Activity
Hoare and Usdin
J. Pharmacol. Exp. Ther. 2000;295:761-770.
ABSTRACT | FULL TEXT  

Cancer and Bone
Guise and Mundy
Endocr. Rev. 1998;19:18-54.
ABSTRACT | FULL TEXT  

Guidelines for the treatment of hypercalcemia associated with malignancy
Nakashima
J Oncol Pharm Pract 1997;3:31-37.
ABSTRACT  

ETIDRONATE FOR HYPERCALCEMIA OF MALIGNANCY
JWatch General 1991;1991:5-5.
FULL TEXT  

Malignant Hypercalcemia: The Choice of Therapy
List
Arch Intern Med 1991;151:437-438.
ABSTRACT